• FingerMotion’s strategy is to rapidly expand its user base through organic means utilizing a broad range of innovative applications
• It handles over 500,000 transactions every day for its mobile payment and recharge service, all facilitated by superior technology
• Technology and innovation are at the center of FingerMotion’s operations and activities and will clearly play a significant role in the company’s future

FingerMotion (OTCQX: FNGR), since its inception back in 2016, has always pushed boundaries with innovation and introducing new ideas. Innovation has always played a central role in what the company does, and it leverages this to expand its market reach and grow market share. The company’s core competencies are mobile payments and recharge platform solutions for the Chinese market (https://ibn.fm/CSTyS). Today, it serves over a billion users in this market, intending to expand to other regions in the future. In 2021 alone, the company has introduced innovative insurance applications collaborating with Xunlian Tanxia Technology and Happy Life Insurance (https://ibn.fm/XIUKB). This innovation trend extends onto its other product offerings that fall into three main categories: Telecommunications Products and Services, SMS and MMS Services, Big Data Insights, and the Rich Communication Services (“RCS”) platform. FingerMotion’s vision is to continue growing its user base, mainly through organic means. It also seeks to leverage this growth and transform it into an ecosystem of users with high engagement rates while utilizing its broad range of innovative applications (https://ibn.fm/w2wNR). So far, the company handles over 500,000 transactions every day for its mobile payment and recharge service (https://ibn.fm/rgfus). These milestones have been achieved through the company’s technology and innovation, and the company seeks to develop further value-added technologies targeting its customer base. FingerMotion’s innovation cuts across its four pillars of growth. These include its flourishing SMS business, strong top-up, mobile recharge business, emerging portal sales, and Insuretech space (https://ibn.fm/pngrc). The company has made incredible strides, with key achievements and milestones that include the launch of its Sapientus offering that capitalizes on big data and market-forming technology. Additionally, FingerMotion has also been responsible for launching business with the three key eCommerce portals in China – JD.com, PinDuoDuo and Alibaba (https://ibn.fm/E1szq). Additionally, the two are intended to play a vital role in the company’s future, especially regarding taking over the Chinese market and expanding to other regions. Also, the company has been very vocal about outpacing changes in technology, which is integral given how fast technology is changing and the potential that it holds in FingerMotion’s market. Technology affects how people learn, think, communicate, conduct business, or even interact with each other. FingerMotion’s move to bank on technology leverages the potential that it has and a consumer base committed to utilizing technology to make their lives easier. For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

• CYBN subsidiary Adelia Therapeutics has reached earn-out milestones.
• Adelia’s earn-out milestones contributed to positive preclinical results with multiple proprietary psychedelic molecules.
• Cybin’s development of these compounds differentiates it from companies focused on naturally occurring psychedelic compounds.

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced that earn-out milestones have been reached by its wholly controlled subsidiary Adelia Therapeutics Inc. These milestones, which were for the period commencing Jan. 1, 2021, add value to Cybin’s pipeline of novel psychedelic compounds (https://ibn.fm/Y1YPb). “These positive catalysts continue to provide the necessary data required to demonstrate that Cybin’s proprietary deuterated psychedelic molecules potentially carry the same pharmacodynamic properties, safety profiles, potency and receptor targeting as their parent molecules,” said Cybin CEO Doug Drysdale. “While the profiles are similar to parent molecules, early research has shown that these proprietary molecules also carry certain characteristics that may lead them to potentially become commercially viable because of their improved stability, bioavailability, controlled psychedelic duration and overall enhanced chemical make-up.” Adelia’s earn-out milestones contributed to positive preclinical results with multiple proprietary psychedelic molecules, the company reported. Those results determined that proprietary deuteration modifications in multiple-lead new chemical entity candidates did not alter pharmacodynamic properties and did not alter safety as assessed in in-vitro toxicity tests as compared to non-deuterated analogs. These promising results add value to the pipeline of proprietary novel psychedelic compounds that Cybin is developing. The results, the company noted, demonstrate that “these molecules perform similarly to the naturally occurring molecules in certain important metrics. The development of these compounds differentiates Cybin from companies focused on naturally occurring psychedelic compounds.” Cybin closed on its acquisition of Adelia in December 2020 in a move that Drysdale stated as “potentially advancing Cybin’s ability to innovate our psychedelic drug development program and diversify beyond major depressive disorder. “Adelia’s focuses on novel delivery methods and innovative therapies may contribute to our goal of therapies with faster onset of action, smoother pharmacokinetic profiles, shorter treatment periods and reduced side effects,” Drysdale continued. “Adelia’s expertise across multiple molecules and multiple indications could potentially give Cybin the ability to address gaps across a larger domain” (https://ibn.fm/XaFk4). Cybin, a leading biotech company focused on progressing psychedelic therapeutics, is on a mission to revolutionize mental health care. The company is focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• PlantX Life recently launched as a seller on both Walmart Canada Marketplace and Hudson’s Bay Marketplace
• The launches appear to be leveraging the changes and trends brought about by the COVID-19 pandemic
• In addition, the agreements are part of PlantX’s growth strategy
• The company will offer thousands of its products on both platforms

As the COVID-19 pandemic upended multiple aspects of life in Canada, it did not spare the retail industry. Here, it forced Canadians to rethink how, where and when they shop, with the paramount consideration in their decision-making process being their personal and family health and safety. Shopping was no longer about what was trendy, cheap or convenient, but how safe it was. This shift instigated a dramatic drop in the number of in-store visits, even for groceries, with shoppers instead opting to go digital. According to a study by KPMG Canada, 66% of Canadians increased their online shopping habits as a result of the pandemic. The 47% of Canadians who shifted to e-commerce do not miss their old way of grocery shopping, while only 15% of Canadians miss their old shopping habits and are eager to return to them (https://ibn.fm/4OX3F). The overall result was that online retail as a share of total retail sales grew from 3.6% in 2019 to 6.2% in 2020 (https://ibn.fm/cqWnH). These trends benefited some e-commerce stores, including Walmart Canada Marketplace, whose e-commerce sales grew by a staggering 229% during the pandemic. In a deal that will allow it to leverage these trends/statistics, as well as Walmart Canada Marketplace’s extensive digital marketing services and customer base, PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) launched as a seller on Walmart Canada Marketplace, fulfilling a June 1 announcement. As part of the new collaboration, PlantX will make available for sell plant-based household supplies and pantry items from various brands, including Made in Nature, Cadia, Chickapea, NuNaturals, Fody, Plant Snacks, and Quantum, with potential opportunities to diversify its offerings on the platform in future (https://ibn.fm/vQ9xo). “We have been focused on executing our growth strategy and our products being added to Walmart Marketplace is another component of expansion efforts,” commented PlantX Founder Sean Dollinger. “With our profile as a seller on this platform now active, we are excited to continue expanding access to our products to customers in Canada.” In the June 1 communique (https://ibn.fm/fiph1), Dollinger had stated that the collaboration demonstrates the demand for PlantX’s products and “redefines PlantX’s potential as a plant-based leader.” The Walmart Canada Marketplace announcement followed on the heels of a May 25 announcement that PlantX had launched as a seller on Hudson’s Bay Marketplace, a diversified retailer. While browsing the online store, customers can expect to find an assortment of indoor live plants, Nootka & Sea’s cosmetics and personal care products, and plant-based pet food from brands such as Evolution Diet and Benevo. Eventually, PlantX intends to offer more than 2,000 products on this online marketplace (https://ibn.fm/F2AfQ). “Witnessing our agreement with Hudson’s Bay Marketplace come to life is beyond encouraging,” stated PlantX CEO Julia Frank. “We hope practical ramifications of these efforts will be tangible, and we are looking forward to working with Hudson’s Bay Marketplace.” With the majority of Canadians having already shifted to online shopping and an equally large proportion stating that they will continue going down that road well into the future, PlantX strategic partnerships appear to be capitalizing on the changes and emerging trends in the food and beverage industry. Vancouver-based PlantX Life is a high-growth technology company focused on consumer-packaged goods (“CPG”) for the plant-based community. The company is committed to educating and empowering those interested in a plant-based lifestyle. “Shop with confidence at Plant X,” reads the company’s website. “We’ve done the work for you and everything we endorse meets our guideline for personal health and wellness morals. If it isn’t plant-based, we don’t offer it.” For more information, visit the company’s websites at www.PlantX.com, www.PlantX.ca, and https://Investor.PlantX.com/ and view PlantX for Plant-Based Investors. To visit the company’s YouTube channel, click here (https://ibn.fm/XiCLc). NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

• GTVH, HyFrontier Technologies working together to offer a patent-pending hydrogen and oxygen delivery system for agriculture.
• Company has seen recent developments that could significantly benefit the entire agricultural industry.
• Duplicating enhanced-growth thunderstorms cause can reduce need for crop rotations, helping millions of people avoid starvation.

A little more than a month after announcing its formal purchase agreement with HyFrontier Technologies (https://ibn.fm/RZkbo), Golden Triangle Ventures (OTC: GTVH) is making good on its commitment to pursue ventures in the technology sector to provide advanced technology for the modern era. GTVH and HyFrontier Technologies are working together to offer a patent-pending, first-of-its-kind hydrogen and oxygen delivery system for agriculture (https://ibn.fm/4jSkX). “This acquisition has been something [we] have been working towards for quite some time,” said Golden Triangle Ventures CEO Steffan Dalsgaard, upon announcing the purchase agreement. “We knew that completing this agreement would show the world that we are fully committed to both our shareholders and the brilliant future of this revolutionary company. . . . In just the past few weeks, there have been developments that could significantly benefit the entire agricultural industry, which have only further bolstered my confidence on the trajectory and path forward.” The mission of HyFrontier Tech is to improve global crop-production efficiency. To do this, the company is developing HyGrO, its patent-pending process and device technology, based on the understanding that lightning and thunderstorms deliver nitrogen and hydrogen to the soil, resulting in enhanced growth. In-house testing shows that hydrogen is capable of increasing crop yields by up to 25% and, in many circumstances, much higher. Larger root systems and better overall plant health were also observed in plants watered with the HyGrO unit. “A bolt of lightning is so powerful, it breaks the covalent bonds of both the air and water it makes contact with to create nitrogen, oxygen and hydrogen, which gets caught up in the rain and downdraft of the storm, falling to the earth, providing critical nutrients plants need,” the company explains. GTVH and HyFrontier believe that duplicating the enhanced growth thunderstorms cause can become a reality, thereby reducing the need for crop rotations and helping millions of people avoid starvation. “Land will yield better results for future generations,” the company continued, “paving the way for a more sustainable future.” HyGrO can be used on any species of plant life in nearly any grow medium; it can also be retrofitted to wellheads for large-scale agricultural projects, indoor grow operations and small farms or utilized for a multitude of residential home and garden applications. Currently, HyFrontier is working with several universities to validate the HyGrO technology, with preliminary indications showing extremely positive results. Golden Triangle Ventures is a multifaceted consulting company with many projects being developed that provide synergistic values in the health, entertainment and technology industries. The company aims to purchase, acquire and/or joint venture with established entities that management can help assist and develop into unique opportunities. Additionally, GTVH provides a professional corporate representation service to different companies in these sectors while consulting on a variety of business-development objectives. The goods and services represented are driven by innovators who have passion for and commitment to these marketplaces. The company plans to utilize relationships and create a platform for new and existing businesses to strengthen their products and/or services. For more information, visit the company’s website at www.GoldenTriangleInc.com. NOTE TO INVESTORS: The latest news and updates relating to GTVH are available in the company’s newsroom at https://ibn.fm/GTVH

• The program’s initial focus is to support those at risk or already diagnosed with diabetes or cardiovascular disease, offering better health management and quality of life
• In the United States, approximately 88 million adults live with prediabetes, and as many as 84% do not know they have it. It is estimated that by 2030, 13.6 million Canadians will be diabetic or prediabetic
• The global point-of-care diagnostics testing market was valued at $30.45 billion in 2021 and is anticipated to grow at a CAGR of 3.25%, resulting in a revenue forecast of $35.74 billion by 2028

Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF), a pharmacy service innovator focused on the acquisition and development of early-stage technologies, has reported success in the pilot rollout for Shoppers Drug Mart(R) and the company’s wholly owned subsidiary HealthTab(TM). HealthTab(TM) is a turnkey point-of-care testing solution for pharmacies to provide a larger role in primary care delivery, which empowers patients to take control of their health (https://ibn.fm/9K873). Avricore Health’s CEO, Hector Bremner, and key team members will conduct regular investor calls to provide progress updates and take questions about the innovative solution and the rollout program. In the first such investor call, which took place July 6, the agenda included opening remarks, team introduction, presentation, updates, and a 30-minute Q&A session. “We have many enthusiastic supporters, and we want to be able to provide a forum to share more insights on our plans and progress. I’m looking forward to taking questions and keeping a regular dialogue going about how we are changing the face of rapid-diagnostics in pharmacy,” Bremner commented (https://ibn.fm/S3DDU). The call came just after the initial systems testing was completed on HealthTab(TM), demonstrating that it was operating successfully after implementation in the first 11 Shoppers Drug Mart locations where it was launched. The rollout is a part of the Master Agreement and Statement of Work. Under this agreement, the initial Ontario locations receive the point-of-care testing platform from HealthTab(TM) that features the Afinion2(TM) blood chemistry analyzers by Abbott Rapid Diagnostics. The program’s initial focus is to screen patients at risk or already diagnosed with diabetes and cardiovascular disease, offering a better way to manage the conditions for a higher quality of life. As key milestones are accomplished, the company will add more locations to the HealthTab(TM) network, further expanding per the Master Agreement with Shoppers Drug Mart Canada. The screening program is an innovative and convenient solution for potentially millions of people with prediabetes or diabetes, a massive market that is constantly expanding. It is estimated that in the United States, there are approximately 88 million adults (more than 1 in 3) living with prediabetes (https://ibn.fm/42OtS). Of these 88 million, more than 84% of them don’t know that they have it. Nearly 13.6 million Canadians are expected to be diabetic or prediabetic by 2030, with many being underdiagnosed (https://ibn.fm/7eHCz). Prediabetes increases the risk of developing Type 2 diabetes, stroke, and heart disease. Additionally, a successful rollout of the HealthTab(TM) platform will help position Avricore Health as a leading company in the point-of-care diagnostics and testing market, which is anticipated to gain momentum in the coming years. The global market was valued at $27.8 billion in 2020 and increased to $30.45 billion in 2021 (https://ibn.fm/8KVTn). Expected to grow at a CAGR of 3.25% from 2021 to 2028, the revenue forecast for 2028 is $35.74 billion. North America was the largest regional market in 2020, accounting for over 34% of the revenue, and is expected to maintain its position throughout the forecasted years. In terms of clinics, pharmacies and retail clinics showed higher use of point-of-care diagnostic systems, followed by physician offices. For more information, visit the company’s website at www.AvricoreHealth.com. NOTE TO INVESTORS: The latest news and updates relating to AVCRF are available in the company’s newsroom at https://ibn.fm/AVCRF

• Industry experts share expertise, insight in next DealMaker webinar.
• Successful Reg A+ offerings tell their stories across multiple mediums.
• DealMaker is building a reputation for its ability to offer services that support companies across a wide array of needs.

With its mission of delivering speed, innovation and efficiency to global capital markets in mind, DealMaker has scheduled its next webinar. Slated for July 20, 2021, at 12 noon ET, the event will feature Don Yocham, executive director of the National Institute of Cannabis Investors, and Ryan Bradford, director of digital marketing at Creative Direct Marketing Group as well as DealMaker’s own Mike Werry, vice president of sales and marketing (https://ibn.fm/lpGbR). Savvy companies know that successful Reg A+ offerings tell their stories across multiple mediums, and DealMaker’s next webinar will delve into the details of what that means. Yocham and Bradford will share their expertise as they examine the way different channels can impact the success of an offering and provide insight to the various tools issuers have to bring their stories to the masses. Click here to register. DealMaker webinars (https://ibn.fm/ZtNnz) are designed to offer invaluable information across diverse but timely topics. The company is quickly building a reputation for its ability to offer a suite of services that support companies across a wide array of needs. DealMaker provides everything from an exclusive new-client onboarding platform that features a digital form that clients can complete and update with one click to its fund formation component that offers enhanced functionality for broker-dealer compliance teams and easy integration with fund management parts. The company also streamlines capital raise transactions, offering a proprietary subscription flow that has streamlined the path for tens of thousands of investors from all over the world to sign and fund — all online. The system’s real-time data optimizes deal flow for deal administrators and offers a variety of advanced payment solutions, making it easier than ever for investors to submit funds. Committed to offering its clients a simpler, cleaner way of doing things on one global platform, DealMaker has become the leading technology solution for companies looking to power their capital raises faster and more efficiently. Companies of all sizes, from startups to blue chip, use DealMaker to launch and market their offerings to investors across the globe. Since commencing operations in 2018, nearly 1,000 capital raises have been completed using DealMaker, including some of the most successful raises in the past three years. For more information about the company, visit www.DealMaker.tech. NOTE TO INVESTORS: The latest news and updates relating to DealMaker are available in the company’s newsroom at https://ibn.fm/Deal

• San Diego-based Tryp Therapeutics is developing new drug candidates with the aim of treating medical conditions that currently have limited effective therapy
• Tryp has solidified an agreement with the University of Michigan’s Chronic Pain & Fatigue Research Center and the Center for Consciousness Science to test synthetic psychedelic drug candidate TRP-8803 to advance its use in upcoming clinical trials
• The Company has also established an agreement with the University of Florida to test its lead drug candidate — TRP-8802 — for certain eating disorders
• Psychedelics are beginning to gain new respect and attention for addressing select neurological conditions as scientists, legislators and former drug opponents re-evaluate their views on the substances’ potential benefits

As a growing number of investigational scientists evaluate the potential of psychedelics to open a new field of medicinal solutions, Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is moving forward with its mission to treat otherwise underserved chronic pain and eating disorder indications using its lead drug candidate TRP-8802, a synthetic psilocybin formulation. On July 7, the Company announced that an additional psilocybin-based formulation, TRP-8803, will be part of a series of upcoming bridging studies at the University of Michigan’s Chronic Pain & Fatigue Research Center and the Center for Consciousness Science in the Department of Anesthesiology. The aim of comparing TRP-8803 with conventional oral formulations of synthetic psilocybin in the studies is to “explore 1) the relationship between a psilocybin-induced increase in neurophysiological complexity and indices of pain in a preclinical model for chronic central pain, 2) the effect of alternative delivery methods of psilocybin on indices of pain and insular glutamate/GABA, and 3) PK analysis for blood samples from both oral and novel methods of delivery of psilocybin,” according to the announcement (https://ibn.fm/XL1B0). Tryp also entered an agreement with the University of Florida to conduct a Phase 2a clinical trial for treating certain eating disorders using TRP-8802, which is being forged in partnership with psychedelic therapy educational platform Fluence (https://ibn.fm/l3ERb) and Contract Research Organization (“CRO”) Clinlogix (https://ibn.fm/UGbSG). The TRP-8803 studies at the University of Michigan aim to similarly advance the drug candidate for neurological-based maladies toward future Phase 2b clinical trials. George Mashour, M.D., Ph.D., will advise the Company on its initial clinical study design for TRP-8803. Dr. Mashour is recognized globally as an expert on the neurobiology of consciousness and general anesthesia and he currently serves as the principal investigator for several NIH grants in the field of neuroscience, academic anesthesiology and translational science, according to the announcement. “I have been impressed with the scientific rigor and innovation from the team at Tryp as well as their collaborative spirit. I look forward to making great strides together toward addressing unmet patient needs in a wide range of indications,” Mashour stated. The University of Michigan has become a hotbed for medicinal psychedelics advocacy, and they believe society has reached a watershed moment for the substances’ acceptance for medical treatments. The Michigan Psychedelic Society was established in 2017 to promote education and harm reduction, and the U-M Student Association for Psychedelic Studies (“SAPS”) was launched the same year, building a steady increase in awareness (https://ibn.fm/nw2P1). The publishing wing of Harvard’s medical school likewise carried an article last month that noted, “Recently, psychedelic drugs have once again taken popular culture by storm. From the psychedelic startup companies newly forming on Wall Street to a recent New York Times article that claims ‘psychedelic drugs are closer to medicinal use ’ it seems that there is a renewed media and medical interest in acid (‘LSD’), mushrooms (psilocybin), ecstasy (‘MDMA’), ayahuasca, DMT (dimethyltryptamine), and ketamine” (https://ibn.fm/posm6). For more information on Tryp Therapeutics, visit the company’s website at www.TrypTherapeutics.com. NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

• Drug delivery platform developer Lexaria Bioscience recently received its 20th patent — granted in Japan for beverages with lipophilic active agents
• The active agents include non-psychoactive cannabinoids and over-the-counter NSAIDS such as ibuprofen and aspirin that target pain and inflammation
• Lexaria’s DehydraTECH platform transforms drugs into a powder or liquid form that maintains the drug’s efficacy and allows it to be assimilated by the body more rapidly than normal oral ingestion of pills
• The company will also announce the latest results from six key R&D projects focusing on concentration levels, tolerability and avoidance of incidental new molecular entities (“NMEs”) soon

Drug assimilation technology innovator Lexaria Bioscience (NASDAQ: LEXX) is demonstrating the versatility of  its DehydraTECH platform with the announcement of a patent for “stable ready-to-drink beverage compositions comprising lipophilic active agents” — the company’s first granted in Japan. “This new patent adds to our existing suite of granted patents spanning the EU, the U.S., India and Australia, and continues to build value for Lexaria shareholders and clients,” CEO Chris Bunka stated (https://ibn.fm/hHDZf). The DehydraTECH technology converts drugs into a powder or liquid form that will make them orally ingestible at a level of quick absorption and efficacy that is competitive with smoked or vaporized drug use but without the risk of lung harm that may be a consequence of inhaling drugs. Processing drugs with DehydraTECH is being further evaluated through the company’s research and development program to establish that the drugs do not undergo unexpected changes in the process that would affect their safe use, and Lexaria expects to report its latest findings among six key R&D projects in the coming months (https://ibn.fm/ck0U3). The patent for beverage compositions with lipophilic active agents in Japan references active ingredients such as non-psychoactive cannabinoids and NSAIDS (ibuprofen, aspirin and similar OTC anti-inflammatory pain relievers). According to the announcement, Lexaria has 13 patent families among its worldwide patent applications. The Japan patent is the third one granted in its third family, and the 20th patent overall. Earlier this month, Lexaria announced its voluntary delisting of its common shares from the Canadian Securities Exchange (CSE ticker LXX) in order to focus its resources on the applied R&D programs, reduce fees and managerial requirements that came with a dual listing and to provide more liquidity for shareholders. “Since Lexaria’s shares began trading on the Nasdaq in January 2021, the overwhelming majority of trading has moved to Nasdaq,” the announcement states (https://ibn.fm/8kqL6). In animal studies, DehydraTECH-delivered drugs have been shown to reach the bloodstream in minutes instead of hours, thanks to molecular delivery through the lymphatic system instead of the digestive system and its “first pass” liver exposure. DehydraTECH thereby eliminates concerns about unwanted tastes and odors accompanying the medicines and increases bio-absorption of the partner drugs into blood circulation by 100 to 500 percent with even greater bio-absorption measured in brain tissue, which establishes the potential for advancing treatment of central nervous system disorders. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Scientific evidence is mounting that SARS-CoV-2 can cause neurological damage in patients hospitalized with the infection.
• A recent study that appeared in the journal JAMA Network Open finds five times increased mortality risk in patients hospitalized with COVID-19, citing encephalopathy as the most common neurological disease found in the clinical setting.
• As more research is needed to understand how COVID-19 affects the brain, Brain Scientific appears poised to offer technology solutions as a leading player in the neurological diagnostics space.

As the world learns more about the novel SARS-CoV-2 virus, the evidence about neurological symptoms developed by patients who suffered from COVID-19 is mounting, and the market for Brain Scientific’s (OTCQB: BRSF) innovative products appears to expand. A recent article published in Medical News Today discusses findings of the observational study examining neurological issues in patients hospitalized with COVID-19. The research which appeared in the journal JAMA Network Open unveils that the most prevalent neurological symptom observed in the clinical setting was acute encephalopathy also finding a relationship between neurological issues and a higher risk of dying in the hospital in patients infected with the SARS-CoV-2 virus (https://ibn.fm/j0F22). Although COVID-19 is considered a respiratory disease that mainly affects patients’ pulmonary systems, research is increasingly documenting that the disease can affect many other organs and systems, including the brain. Since the start of the pandemic, it has been observed in a clinical setting that some patients with COVID-19 have also developed neurological symptoms. However, more than a year into the pandemic, medical professionals and scientists alike still do not fully understand the prevalence of neurological problems or their relationship with mortality risk. To help fill this literature gap, Dr. Sherry Chou and her research team from the University of Pittsburgh School of Medicine performed an interim analysis of patient data collected from two large global consortia involving 3,744 patients across three cohorts. The study’s goal was to examine the incidence, type and outcomes of neurological manifestations among patients hospitalized with COVID-19. What data revealed was astonishing. The first cohort involving 3,055 patients hospitalized with COVID-19, both with and without neurological symptoms, unveiled that the most prevalent clinically reported neurological sign was acute encephalopathy, found in 50% of patients, while the most frequent self-reported symptom was headache (38%), and the loss of taste or smell (28%). The second and third cohorts involving patients with confirmed neurological issues and those who had received a neurological consultation also show encephalopathy as the most common neurological issue (53% and 24%, respectively). Again, it was followed by headaches and the loss of taste and smell as the most common self-reporting neurological symptoms. Research also reveals that if a patient has neurological issues resulting from COVID-19, it increases their risk of dying while in hospital by five times. Authors suggest that a formal neurological consultation may be needed in cases where doctors suspect neurological symptoms in individuals testing positive for COVID-19. Although an association between neurological issues in COVID-19 patients and an increased risk of in-hospital mortality has been established, more research is needed to identify if these neurological symptoms are causing the increase in mortality. Notwithstanding some practical limitations of the study, it lays the groundwork for future research involving standardized protocols, which may be able to track patients with neurological issues after they leave the hospital. As we learn more about the novel SARS-CoV-2 virus, it is becoming increasingly clear that neurological diagnostics will be at the center of the future post-COVID-19 health care of patients who suffered from the infection. Dr. Chou, the lead author of the study, emphasizes that even if we eradicate the pandemic, there are already millions of survivors who need neurological help, and there is still plenty of work in years to come. As a commercial-stage health care company focused on developing innovative medical devices and software disrupting the brain diagnostics market, Brain Scientific is poised to be at the center stage of neurological diagnostics space offering solutions for this growing public health problem with its two commercialized and FDA-cleared devices, NeuroCap(TM) and NeuroEEG(TM). Committed to a vision to allow medical professionals to conduct brain activity studies and collect diagnostic information more quickly, Brain Scientific appears well-positioned to offer solutions for the growing market need in the post-pandemic world. For more information, visit the company’s website at www.BrainScientific.com/Invest-Now. NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

• Experienced automotive industry veteran joins IMC as new president.
• Dubois has served as a leader at some of the most prestigious automotive organizations in the industry.
• New exec looking to build team that will lead Canadian operations to surpass even most optimistic projections.

DSG Global (OTCQB: DSGT) has announced that Christian Dubois, an auto executive with more than three decades of experience in the automotive industry, has accepted the role of president of Imperium Motors Canada, a division of DSGT’s Imperium Motor Corp. (“IMC”). IMC is an EV sales, manufacturing and marketing company that is gaining momentum and gathering attention for offering a variety of affordable electric vehicles equipped for the North American market. “Great companies are built on quality personnel, and we have exceeded any expectations,” said DSG Global CEO Robert Silzer. “Growth at times takes longer than planned; however, it’s obvious the hires of late are the best in the industry and will certainly assist in our corporate growth.” Dubois has served as a leader at some of the most prestigious automotive organizations in the industry. Most recently, he was regional director of operations and regional director of acquisitions and dealer development with the Dilawri Group of Companies, Canada’s largest automotive group. Dubois has also been with BMW Canada and Mercedes-Benz Canada. Dilawri employs more than 4,000 employees and has 76 franchised dealerships representing 35 automotive brands. And those aren’t the only numbers worth mentioning from Dubois’s stellar career. Thus far, he has managed 41 stores, worked with the executive teams of most OEMs, and represented dealers on multiple dealer councils. Retailers under his supervision have sold an estimated 80,000 cars and trucks, resulting in company revenues of more than $6 billion. He has been instrumental in acquiring 17 dealerships and in winning 13 open points; he has also won 11 Retailer of the Year awards. “Christian’s notoriety and experience in the automotive industry will allow Imperium to advance quickly toward becoming a top electric vehicle company,” said Imperium Motors president and CEO Rick Curtis. “He has strong plans for achieving strong sales rapidly, and his track record speaks for itself. Christian will be invaluable to our future success.” Dubois joins Imperium Motor Corp. as it focuses on making its mark in the U.S. EV space. The company is committed to offering EVs that feature a great design and a green mindset, as well as outstanding performance and functionality. IMC offerings will include high-speed, mid-speed and low-speed electric cars, trucks, SUVs, vans, buses and scooters. “Everyone by now has heard that the future is electric, and Imperium is about to introduce electric mobility in new segments and to new customers with affordable products that will redefine value,” said Dubois. “I am extremely excited to join Imperium and build the team that will lead our Canadian operations to surpass even the most optimistic projections.” DSG Global is an emerging global technology company with an array of interconnecting businesses in some of the fastest-growing market sectors. With roots in the golf industry, in which it specializes in fleet management with patented analytics, mobile touch-screen engagement and electric golf carts under the Vantage Tag Systems (“VTS”) brand, the company is moving quickly with road-ready electric vehicles for sale in the first quarter of 2021 through its Imperium Motor Company subsidiary. To learn more about the company, please visit www.DSGTGlobal.com. NOTE TO INVESTORS: The latest news and updates relating to DSGT are available in the company’s newsroom at https://ibn.fm/DSGT